Pharmacom Total Assets from 2010 to 2026
| PHMB Stock | USD 0.0001 0.00 0.00% |
Total Assets | First Reported 2010-12-31 | Previous Quarter 129.2 K | Current Value 135.7 K | Quarterly Volatility 27.6 K |
Check Pharmacom Biovet financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pharmacom Biovet's main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 475.5 K or Total Revenue of 0.0, as well as many indicators such as . Pharmacom financial statements analysis is a perfect complement when working with Pharmacom Biovet Valuation or Volatility modules.
Pharmacom | Total Assets | Build AI portfolio with Pharmacom Stock |
Latest Pharmacom Biovet's Total Assets Growth Pattern
Below is the plot of the Total Assets of Pharmacom Biovet over the last few years. Total assets refers to the total amount of Pharmacom Biovet assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Pharmacom Biovet books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Pharmacom Biovet's Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pharmacom Biovet's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 112.36 K | 10 Years Trend |
|
Total Assets |
| Timeline |
Pharmacom Total Assets Regression Statistics
| Arithmetic Mean | 108,381 | |
| Geometric Mean | 94,800 | |
| Coefficient Of Variation | 25.47 | |
| Mean Deviation | 12,221 | |
| Median | 112,363 | |
| Standard Deviation | 27,605 | |
| Sample Variance | 762M | |
| Range | 131.2K | |
| R-Value | 0.52 | |
| Mean Square Error | 590.2M | |
| R-Squared | 0.27 | |
| Significance | 0.03 | |
| Slope | 2,861 | |
| Total Sum of Squares | 12.2B |
Pharmacom Total Assets History
About Pharmacom Biovet Financial Statements
Pharmacom Biovet stakeholders use historical fundamental indicators, such as Pharmacom Biovet's Total Assets, to determine how well the company is positioned to perform in the future. Although Pharmacom Biovet investors may analyze each financial statement separately, they are all interrelated. For example, changes in Pharmacom Biovet's assets and liabilities are reflected in the revenues and expenses on Pharmacom Biovet's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Pharmacom Biovet. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Assets | 129.2 K | 135.7 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| JBL | Jabil Circuit | |
| MRK | Merck Company | |
| AMGN | Amgen Inc |
Check out the analysis of Pharmacom Biovet Correlation against competitors. For information on how to trade Pharmacom Stock refer to our How to Trade Pharmacom Stock guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pharmacom Biovet. If investors know Pharmacom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pharmacom Biovet listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Pharmacom Biovet is measured differently than its book value, which is the value of Pharmacom that is recorded on the company's balance sheet. Investors also form their own opinion of Pharmacom Biovet's value that differs from its market value or its book value, called intrinsic value, which is Pharmacom Biovet's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pharmacom Biovet's market value can be influenced by many factors that don't directly affect Pharmacom Biovet's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pharmacom Biovet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pharmacom Biovet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pharmacom Biovet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.